Published in J Virol on January 01, 1997
The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol (2007) 1.77
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J Virol (1999) 1.39
Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol (1999) 1.11
T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol (1998) 1.10
Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol (1998) 1.10
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One (2011) 1.01
Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol (2006) 0.96
Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol (2007) 0.95
Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol (2001) 0.90
Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol (2007) 0.88
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol (2006) 0.88
Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection. J Virol (2008) 0.84
Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks. J Virol (2011) 0.82
Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks. J Virol (2001) 0.79
Novel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins. J Virol (2013) 0.78
Potential Susceptibility Mutations in C Gene for Hepatitis B-Related Hepatocellular Carcinoma Identified by a Two-Stage Study in Qidong, China. Int J Mol Sci (2016) 0.75
Advances and Challenges in Studying Hepatitis B Virus In Vitro. Viruses (2016) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol (1973) 45.44
Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol (1982) 5.48
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Purification of human T and B lymphocytes. J Immunol (1974) 4.00
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature (1987) 2.85
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol (1994) 2.29
Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol (1987) 2.25
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med (1987) 1.78
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol (1995) 1.71
Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J Immunol (1993) 1.66
Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J (1984) 1.54
Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci U S A (1988) 1.41
Vaccination to prevent persistent viral infection. J Virol (1993) 1.39
Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology (1995) 1.32
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology (1995) 1.24
Isolation of B and T lymphocytes by nylon fiber columns. Tissue Antigens (1977) 1.18
Chronic hepatitis and hepatocellular carcinoma associated with woodchuck hepatitis virus. Am J Pathol (1982) 1.18
Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B. Clin Exp Immunol (1986) 1.14
Mitogen-induced replication of woodchuck hepatitis virus in cultured peripheral blood lymphocytes. Science (1988) 1.10
Protective immunisation against hepatitis B with an internal antigen of the virus. J Med Virol (1987) 1.05
Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine (1993) 1.00
Protection of woodchucks from infection with woodchuck hepatitis virus by immunization with recombinant core protein. J Gen Virol (1989) 0.95
A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice. Virology (1995) 0.93
Viral mutations, TCR antagonism and escape from the immune response. Curr Opin Immunol (1995) 0.93
In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection. Hepatology (1995) 0.92
Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein. Virology (1991) 0.92
Hepatitis B core antigen-specific IFN-gamma production of peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection. J Immunol (1989) 0.90
Recognition of B and T cell epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV 01 Campos. Virology (1994) 0.88
Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model. Clin Immunol Immunopathol (1996) 0.87
HLA-DR typing: a comparison between nylon wool adherence and T cell rosetting in the isolation of B cells. J Immunol Methods (1981) 0.86
Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein. J Virol (1992) 0.85
Characterization of cell mediated immune responses to the hepatitis B core protein in man. Clin Exp Immunol (1987) 0.79
Technical modifications for antibody-dependent cell-mediated cytotoxicity versus separated T and B lymphocytes: T- and B-cell separation by nylon wool columns. Transplant Proc (1978) 0.77
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR (2001) 4.96
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 4.13
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med (1999) 2.82
CaMKIIalpha 3' untranslated region-directed mRNA translocation in living neurons: visualization by GFP linkage. J Neurosci (2000) 2.64
A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry (1995) 2.57
Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. Neuroreport (2000) 2.49
Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther (1998) 2.29
Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology (1995) 2.25
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA (2001) 2.24
Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke (1999) 2.21
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke (1999) 2.17
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke (2001) 2.16
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Mol Cell Biol (2001) 2.06
Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet (1995) 2.03
Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology (2001) 2.02
Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells. Neurosurgery (2001) 1.87
Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group. Stroke (1999) 1.82
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol (2001) 1.78
Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A (1992) 1.77
High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol (2003) 1.73
Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. Neuroreport (2001) 1.70
Comparison of solid phase test systems for demonstrating antibodies against hepatitis A virus (anti-Hav) of the IgM-class. J Med Virol (1980) 1.68
Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med (2000) 1.67
Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA (2001) 1.64
Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke (1998) 1.64
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke (1996) 1.55
Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology (1996) 1.54
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology (2000) 1.48
Atomic-beam alignment of inorganic materials for liquid-crystal displays. Nature (2001) 1.48
Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett (2001) 1.48
Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection. J Clin Microbiol (1981) 1.48
A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood (1991) 1.47
Antibodies to hepatitis C virus. Lancet (1989) 1.47
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes (1997) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch Intern Med (2000) 1.44
Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Nucleic Acids Res (1996) 1.43
Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J (1997) 1.40
MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. Neurology (2005) 1.40
Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience (2007) 1.40
A mitochondrial DNA sequence is associated with abnormal pollen development in cytoplasmic male sterile bean plants. Plant Cell (1992) 1.39
Characterization of a heat-stable protease of Pseudomonas fluorescens P26. Appl Microbiol (1973) 1.38
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke (2001) 1.38
Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy. J Urol (2006) 1.38
Prevalence of antibodies to hepatitis C virus in patients on peritoneal dialysis--a multicenter study. Clin Nephrol (1993) 1.37
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry (2000) 1.36
Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay (1998) 1.36
Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res (1997) 1.36
Core structure of the outer membrane lipoprotein from Escherichia coli at 1.9 A resolution. J Mol Biol (2000) 1.36
The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site. J Biol Chem (2000) 1.35
Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol (2007) 1.35
Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J (2001) 1.33
Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia (2001) 1.33
An epidemiological survey of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand (1989) 1.33
Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods (2002) 1.30
Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods (1988) 1.29
Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay. Eur J Clin Microbiol Infect Dis (1995) 1.28
A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol (2001) 1.27
The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem (1993) 1.27
The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene (1994) 1.26
Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol (1996) 1.25
NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. J Biol Chem (2001) 1.25
Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites. Nature (2001) 1.24
Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. Diabetologia (2001) 1.24
The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology (1995) 1.24
A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand (1991) 1.23
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J Virol (2007) 1.23
Recognition of the highly conserved GTPase center of 23 S ribosomal RNA by ribosomal protein L11 and the antibiotic thiostrepton. J Mol Biol (1991) 1.23
Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal (2001) 1.23
Surface salt bridges stabilize the GCN4 leucine zipper. Protein Sci (1998) 1.23
Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patients. J Pathol (2008) 1.23
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke (2001) 1.23
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol (1999) 1.22
Intention to screen for colorectal cancer among white male employees. Prev Med (1998) 1.20
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology (1997) 1.20
Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant (2001) 1.20
Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics (2001) 1.20
A suggested extension of the HCV ISDR does not alter our former conclusions on its predictive value for IFN response. J Hepatol (1999) 1.19
Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol (1991) 1.18
Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model. Biochemistry (1999) 1.18
Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol (2000) 1.18
The diagnosis of diabetic retinopathy. Ophthalmoscopy versus fundus photography. Ophthalmology (1993) 1.18
Comparison of two different enzyme immunoassays for detection of immunoglobulin M antibodies against tick-borne encephalitis virus in serum and cerebrospinal fluid. J Clin Microbiol (1981) 1.17
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol (2010) 1.16
Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods (1994) 1.14
Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis (2010) 1.13
Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology (1993) 1.13